Business Context and Reporting Period
This Form 6-K filing by Compugen Ltd., an Israeli biotechnology company, serves as a notice of the Annual General Meeting of Shareholders scheduled for April 15, 2010. The filing includes the Notice of Meeting and Proxy Statement, soliciting shareholder votes on corporate governance matters. The record date for shareholders entitled to vote is March 9, 2010.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity for the current or prior periods. It references the Audited Consolidated Financial Statements for the year ended December 31, 2009, as other business to be presented at the meeting, but does not include the figures within this document.
Capitalization details provided include:
- Outstanding Shares: 33,119,432 ordinary shares as of March 9, 2010.
- Nominal Value: NIS 0.01 per share.
- Current Authorized Capital: NIS 500,000 divided into 50,000,000 shares.
Material Changes and Corporate Actions
The filing outlines several material proposals to be voted upon by shareholders:
- Board Composition: Election of four directors (Prof. Ruth Arnon, Mr. Martin Gerstel, Mr. Dov Hershberg, Mr. Alex Kotzer) and re-election of three external directors (Prof. Yair Aharonowitz, Dr. Arie Ovadia, Prof. Joshua Shemer).
- Executive Leadership Change: Mr. Dov Hershberg resigned as Chairman on March 1, 2010, following the election of Dr. Anat Cohen-Dayag as President and CEO. Mr. Hershberg continues as a Director.
- Chairman Compensation: Approval of a gross monthly salary of 42,000 NIS (approx. $11,350) and a grant of 125,000 stock options for Chairman Martin Gerstel, effective January 1, 2010. Mr. Gerstel waived a potential 2009 cash bonus contingent on this approval.
- Capital Increase: Proposal to increase authorized share capital from NIS 500,000 (50 million shares) to NIS 1,000,000 (100 million shares).
- Auditor Appointment: Re-appointment of Kost, Forer, Gabbay & Kasierer (Ernst & Young Global) as independent auditors for the 2010 fiscal year.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future business outlook, financial guidance, or specific risk factors. It notes that the Company urges shareholders to review the Annual Report on Form 20-F for comprehensive information. The document highlights regulatory requirements under the Israeli Companies Law regarding the election of external directors, specifically the need for majority support including non-controlling shareholders.
Investor Verification Checklist
- Verify the outcome of the vote on the increase of authorized share capital to 100 million shares.
- Confirm the final compensation package approved for Chairman Martin Gerstel, including the vesting schedule of the 125,000 options.
- Review the full Audited Consolidated Financial Statements for the year ended December 31, 2009, which are referenced but not included in this filing.
- Monitor the transition of leadership following Dr. Anat Cohen-Dayag's appointment as CEO.
- Check the beneficial ownership table for major shareholders (ClearBridge Advisors, Morgan Stanley, Martin Gerstel) for any subsequent changes.